Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors

Authors

Leighl NB; Laurie SA; Knox JJ; Ellis PM; Shepherd FA; Burkes RL; Vincent M; Pond GR; Zwiebel JA; Moore MJ

Journal of Clinical Oncology, Vol. 23, No. 16_suppl, pp. 7253–7253

American Society of Clinical Oncology (ASCO)

6 2005

10.1200/jco.2005.23.16_suppl.7253

0732-183X

Gregory Pond

Peter Ellis